Integra LifeSciences Q4 adj EPS $0.97 (+9% YoY); FY24 GAAP EPS ($0.09); 2025 adj EPS guidance $2.41-$2.51

INTEGRA LIFESCIENCES HOLDINGS CORP

2024-FY EPS reported -$0.09 revenue$1,610,527,000

Q4 2024: rev $442.6M (+11.5% rep, +3.5% org); adj EPS $0.97 vs $0.89; GAAP EPS $0.25 flat YoY.
FY2024: rev $1,610.5M (+4.5% rep, -1.3% org); GAAP EPS ($0.09) vs $0.84; adj EPS $2.56 vs $3.10.
FY2025 guidance: rev $1,650M-$1,715M (+2.4-6.5% rep, +1.0-5.0% org); adj EPS $2.41-$2.51 (below 2024 adj EPS $2.56).
Q1 2025 guidance: rev $375M-$385M (+1.6-4.4% rep); org rev -6.2% to -3.5% due to ship holds & Integra Skin delays.
Net debt $1.5B; leverage ratio 4.0x; FY2024 cash from ops $129.4M, capex $104.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.